Abstracts tagged "Enthesitis"

Abstract Number: 1874 • 2017 ACR/ARHP Annual Meeting
Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients
Stephanie Tom^1,2, Yujie Zhong³, Richard J. Cook⁴, Sibel Z. Aydin^5,6, Gurjit S. Kaeley⁷ and Lihi Eder^8,9, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Florida, Ponte Vedra Beach, FL, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects approximately a third of patients with psoriatic arthritis (PsA) and is often considered the earliest site of inflammation. The accuracy of clinical…
Abstract Number: 2311 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Juvenile Spondyloarthritis Disease Activity Index and Its Comparison with Adult Spondyloarthritis Disease Activity Scores
Abhishek Zanwar, Sanat Phatak and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Among JIA children with Enthesitis related arthritis (ERA) category have more pain, poorer health status and are less likely to achieve or maintain sustained…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 2878 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, Yanli Zhuang⁴, William Barchuk⁵, Xie L. Xu⁵ and Elizabeth Hsia⁴, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Geneva University Hospital and University of Geneva, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: Evaluate efficacy and safety of guselkumab (GUS) in patients (pts) with active psoriatic arthritis (PsA) over 56 weeks (wks). Methods: Pts w/active PsA (defined…
Abstract Number: 3161 • 2016 ACR/ARHP Annual Meeting
The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis
Ari Polachek¹, Richard J. Cook², Vinod Chandran¹, Fatima Abji¹, Dafna D Gladman³ and Lihi Eder⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is an important pathophysiologic component in psoriatic arthritis (PsA). Ultrasound is emerging as an optimal method to evaluate enthesitis. HLA genes are implicated…
Abstract Number: 147 • 2016 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Subclinical Enthesitis in Patients with Psoriasis
Elzem Bolkan Günaydın¹, Perihan Aladağ², Duygu Tecer¹, Işıl Saadet Yenice¹, Esra Adışen² and Feride Nur Göğüş³, ¹Physical Medicine and Rehabilitation, Division of Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey, ²Dermatology, Faculty of Medicine, Gazi University, Ankara, Turkey, ³Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey
Background/Purpose: Psoriasis is a diseases with diverse skeletal manifestations of which enthesistis is the primary lesion. However, enthesitis may often develop without any symptoms or…
Abstract Number: 165 • 2016 ACR/ARHP Annual Meeting
The Apparent Diffusion Coefficient As a Quantitative Imaging Biomarker of Therapeutic Response in Enthesitis-Related Arthritis
Timothy Bray¹, Kanimozhi Vendhan¹, Nicola Ambrose², David Atkinson¹, Shonit Punwani¹, Corinne Fisher², Debajit Sen², Yiannis Ioannou² and Margaret Hall-Craggs¹, ¹Centre for Medical Imaging, UCL, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose : Early treatment in enthesitis-related arthritis (ERA) may have a disease-modifying effect with consequently improved outcomes. However, disease activity may be difficult to assess,…
Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Kliniken GmbH, Hamburg, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 386 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Clinc Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…
Abstract Number: 959 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Philip J Mease¹, Masato Okada², Mitsumasa Kishimoto², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Susan R Moriarty³, Chin H. Lee³ and Dafna D Gladman⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is an IgG4 monoclonal antibody that binds with high affinity and specificity to the proinflammatory cytokine IL-17A. In this phase 3 study…
Abstract Number: 960 • 2016 ACR/ARHP Annual Meeting
Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Laura Savage¹, Mark Goodfield², Elizabeth M.A. Hensor³, Paul Emery³ and Dennis McGonagle⁴, ¹NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Subclinical enthesopathy is recognised in up to 50% of psoriasis patients and is thought to precede inflammatory PsA. It is not known if effective…
Abstract Number: 1312 • 2016 ACR/ARHP Annual Meeting
Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Satoshi Inotani^1,2,3,4, Yoshinori Taniguchi⁵, Takashi Karashima⁶, Yasuhiko Yoshinaga⁷, Hirofumi Nishikawa⁸, Natsuki Maeda⁹, Shimpei Fujimoto⁸ and Yoshio Terada¹⁰, ¹internal medicine, Chikamori Hospital, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi medical school, Nankoku, Japan, ³Urology, Kochi medical school, Nankoku, Japan, ⁴Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ⁵Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ⁶Urology, Kochi University, Nankoku, Japan, ⁷Kurashiki Medical Center, Kurashiki, Japan, ⁸Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ⁹Endocrinology,Metabolism,Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ¹⁰Kochi University, Nankoku, Japan
Background/Purpose: To evaluate the incidence of reactive arthritis (ReA), uveitis and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy (iBCG). Methods: The…
Abstract Number: 1325 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Manifestations in Ebola Survivors
Duane Pearson¹, Lisa Davis², John Frankhauser³ and Liron Caplan⁴, ¹Division of Rheumatology, University of Colorado, Aurora, CO, ²Div of Rheumatology, Denver Health, Denver, CO, ³Serving In Mission, Monrovia, Liberia, ⁴Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Musculoskeletal complaints are common among survivors of Ebola Virus Disease (EVD) and can have clinical impacts beyond two years post-convalescence. The frequency of these…
Abstract Number: 2743 • 2016 ACR/ARHP Annual Meeting
Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
John Kelsall¹, Pauline Boulos², Regan Arendse³, Michelle Teo⁴, Anna Jaroszynska⁵, Michael Starr⁶, Alexander Tsoukas⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Cathy Tkaczyk¹¹, Francois Nantel¹², Brendan Osborne¹¹ and Allen J Lehman¹⁰, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁵Private practice, Burlington, ON, Canada, ⁶Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁷McGill University, Montreal, QC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown associations between swelling or tenderness of specific joints in RA patients and patient pain. This analysis aimed to describe the…
Abstract Number: 3157 • 2016 ACR/ARHP Annual Meeting
The Association Between Sonographic Enthesitis and Radiographic Damage in Psoriatic Arthritis
Ari Polachek¹, Dafna D Gladman², Richard J. Cook³, Vinod Chandran⁴ and Lihi Eder⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a common clinical finding and a key pathogenic feature in psoriatic arthritis (PsA). Ultrasound is emerging as a preferred method to assess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].